Differences
This shows you the differences between two versions of the page.
| Both sides previous revisionPrevious revision | |
| nsaids [2026/07/10 01:44] – [precautions] gary1 | nsaids [2026/07/10 09:28] (current) – [precautions] gary1 |
|---|
| *in addition, patients with **[[asthma]]**, nasal polyps or with past history of allergic reaction are at higher risk of having an life threatening acute allergic reaction | *in addition, patients with **[[asthma]]**, nasal polyps or with past history of allergic reaction are at higher risk of having an life threatening acute allergic reaction |
| ***pregnancy** | ***pregnancy** |
| * should NOT be used after 20wks gestation as risk to fetus developing PDA is significant | * should NOT be used after 20wks gestation as they can cause premature ductus arteriosus closure, fetal renal injury, oligohydramnios, bleeding effects, and delayed labour or birth |
| * if used prior to 20wks gestation clinician should consider if they believe benefits outweigh risks of slightly increased miscarriage rates or minor fetal abnormalities | * if used prior to 20wks gestation clinician should consider if they believe benefits outweigh risks of slightly increased miscarriage rates or minor fetal abnormalities |
| | * in the 2nd TM, there appears to be risk of fetal renal dysfunction and oligohydramnios, sometimes after relatively short exposure |
| * does not appear to increase risk of major congenital abnormalities when taken in 1st TM according to this large 2026 study (([[https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005063|2026: First-trimester nonsteroidal anti-inflammatory drugs exposure and risk of major congenital malformations: A retrospective register-based cohort study]])), but best avoided if possible given other studies have given conflicting results such as this 2024 systematic review and meta-analysis which suggested increase risk of congenital heart defects and gastrochisis but no increase risk of spontaneous miscarriage(([[https://www.sciencedirect.com/science/article/abs/pii/S0890623824000285|2024: Pregnancy outcomes and birth defects in offspring following Non-steroidal anti-inflammatory drugs exposure during pregnancy: A systematic review and meta-analysis]])) | * does not appear to increase risk of major congenital abnormalities when taken in 1st TM according to this large 2026 study (([[https://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1005063|2026: First-trimester nonsteroidal anti-inflammatory drugs exposure and risk of major congenital malformations: A retrospective register-based cohort study]])), but best avoided if possible given other studies have given conflicting results such as this 2024 systematic review and meta-analysis which suggested increase risk of congenital heart defects and gastrochisis but no increase risk of spontaneous miscarriage(([[https://www.sciencedirect.com/science/article/abs/pii/S0890623824000285|2024: Pregnancy outcomes and birth defects in offspring following Non-steroidal anti-inflammatory drugs exposure during pregnancy: A systematic review and meta-analysis]])) |
| *post-partum period in those who had pre-eclampsia or premature delivery | *post-partum period in those who had pre-eclampsia or premature delivery |
